Which oral muscle relaxant is safe for an elderly patient (≥65 years) needing short‑term therapy, without severe hepatic impairment or uncontrolled hypertension, and can be dose‑adjusted for frailty or renal dysfunction?

Avoid Traditional Muscle Relaxants in the Elderly

Traditional oral muscle relaxants (cyclobenzaprine, methocarbamol, carisoprodol, chlorzoxazone, metaxalone, orphenadrine) should be avoided in elderly patients ≥65 years, as they are listed in the 2019 AGS Beers Criteria as potentially inappropriate medications due to increased risk of sedation, falls, fractures, and lack of efficacy in chronic pain. 1

Why Traditional Muscle Relaxants Are Problematic

The evidence is clear and consistent across multiple high-quality guidelines:

• No direct muscle relaxation occurs – These agents do not actually relax skeletal muscle despite their name 2
• No efficacy in chronic pain – Studies show no benefit beyond placebo for chronic musculoskeletal conditions 2
• High adverse effect burden – Sedation, confusion, anticholinergic effects, and CNS depression are common 1, 3
• Increased injury risk – A 32% increased risk of injury (falls, fractures) in elderly users compared to non-users 4, with 333 patients needing treatment to cause 1 additional injury 5

Specific Agents to Avoid

• Cyclobenzaprine: Structurally identical to amitriptyline with similar anticholinergic toxicity 3, 6
• Carisoprodol: Controlled substance with abuse potential; 73% increased injury risk 4; removed from European markets 3
• Methocarbamol: 42% increased injury risk 4
• Metaxalone, chlorzoxazone, orphenadrine: All carry significant CNS and anticholinergic risks 1, 6

What IS Acceptable: Baclofen (With Major Caveats)

Baclofen is the only muscle relaxant that may be considered in elderly patients, but ONLY if:

1. eGFR ≥60 mL/min – Reduce dose if eGFR 30-60; avoid completely if eGFR <30 or on dialysis 7
2. Used for true spasticity (not general musculoskeletal pain) from CNS injury, demyelinating disease, or neuromuscular disorders 3
3. Started at very low doses with gradual titration to minimize dizziness, somnolence, and GI symptoms 3
4. Monitored closely for neurotoxicity and hemodynamic instability 7
5. Tapered slowly if discontinuing after prolonged use (risk of delirium and seizures) 3

Why Baclofen Is Different

Baclofen is a GABA-B agonist with documented efficacy for spasticity and some evidence for trigeminal neuralgia 2. However, it requires renal dose adjustment and carries serious toxicity risks in kidney disease 7.

Recommended Alternatives for Musculoskeletal Pain

Instead of muscle relaxants, the 2020 JAGS guidelines recommend 2:

For acute musculoskeletal pain:

• Topical NSAIDs (diclofenac, ketoprofen) – High safety due to low systemic absorption
• Short-term oral NSAIDs at lowest effective dose with PPI if needed (avoid in age ≥75 or cardiovascular risk)
• Acetaminophen for mild-moderate pain

For chronic musculoskeletal pain (fibromyalgia, widespread pain):

• Duloxetine (SNRI antidepressant) – First-line with strong evidence
• Pregabalin or gabapentin – Start low (pregabalin 25-50 mg/day, gabapentin 100-200 mg/day) and titrate slowly
• Low-dose TCAs (if anticholinergic burden acceptable)

For spasticity specifically:

• Baclofen (with renal precautions above)
• Tizanidine (alpha-2 agonist) – May be considered but requires monitoring for hypotension and hepatotoxicity

Critical Clinical Pitfalls

1. Don't prescribe based on "muscle spasm" diagnosis alone – Most musculoskeletal pain does not involve true spasm requiring pharmacologic intervention 3

2. Don't assume normal creatinine means normal renal function – Calculate eGFR; elderly patients often have reduced GFR despite normal creatinine due to decreased muscle mass 8

3. Don't continue muscle relaxants chronically – Even if started acutely, reassess within 1-2 weeks; no evidence supports long-term use for most conditions 9

4. Don't combine with other CNS depressants – Risk multiplies with benzodiazepines, opioids, or sedating antihistamines 1

5. Screen for fall risk factors – History of prior falls increases injury risk 3-fold when muscle relaxants are added 5

Algorithm for Decision-Making

Elderly patient requests muscle relaxant
↓
Is this TRUE SPASTICITY from CNS/neuromuscular disease?
├─ NO → Do NOT prescribe traditional muscle relaxants
│         Consider: topical NSAIDs, duloxetine, or gabapentinoids
│
└─ YES → Check eGFR
          ├─ <30 mL/min → AVOID baclofen; consider physical therapy
          ├─ 30-60 mL/min → Baclofen possible with 50% dose reduction
          └─ ≥60 mL/min → Baclofen acceptable; start 5 mg TID, titrate slowly

The bottom line: In real-world geriatric practice, the safest answer is that NO traditional muscle relaxant is truly "okay" for routine use in the elderly. The risk-benefit ratio consistently favors alternative therapies with better safety profiles and actual evidence of efficacy 1, 4, 9.